Table 1.

Biochemical Parameters on a Subject with HCS

	Baseline (8/2013)	3 days after 1st denosumab (10/2013)	5 days before 2nd denosumab (4/2014)	1 day before 3rd denosumab (12/2014)	1 day before 4th denosumab (7/2015)	5 days after 5th denosumab (10/2015)	Last follow-up (3/2016)
Calcium (mg/dL) (8,9–10,1)	9.2	8.4	9.9	9.6	9.8	9.0	9.2
Phosphorous (mg/dL) (2,4-4,1)	3.1	2.3	3.0	3.0	3.4	2.7	3.0
PTH (pg/mL) (10–55)	29	33	28	31	25	64	19
25OHD (ng/mL) (>30)	34.6	31.4	40.0	30.5	31.4	32.1	24
CTX (pg/mL) (100–670)	225	63	220	189	277	33	416
BSAP (UI/L) (6–23)	11	11	9	10	9	9	9
P1NP (ng/mL) (19,3–76,3)	20,5	21.1	/	16.0	20.0	11.2	34.3
RANKL (pmol/L) (0,022–0.282)*	0.451	0.008	/	0.292	0.269	0.008	0.328
OPG (pmol/L) (4,850–6,840)*	1.244	1.021	/	1.411	1.539	1.422	1.092
RANKL/OPG ratio (0,004–0,041)	0.362	0.007	/	0.206	0.174	0.005	0.300

PTH= Parathyroid hormone, 25OHD= 25 hydroxy Vitamin D, CTX= C-Telopeptide of type I collagen, BSAP= Bone specific alkaline phosphatase, P1NP= Procollagen I intact N-terminal peptide, RANKL= Receptor activator of nuclear factor Kappa-B ligand, OPG= Osteoprotegerin; Normal range values are in parenthesis.

^*Normal range was established by measuring serum RANKL and OPG in ten age-matched female normal volunteers.